Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Acute MI Workup in Emergency Departments Varies by Sex and Race

News Daily News

Acute MI Workup in Emergency Departments Varies by Sex and Race

Michael O'Riordan

May 11, 2022

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

TCTMD’s Top 10 Most Popular Stories for April 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

May 02, 2022

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

News Daily News

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

March 25, 2022

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

March 22, 2022

March 2022 News Roundup

News Opinion CV Team Dispatch

March 2022 News Roundup

March 01, 2022

February 2022 News Roundup

News Opinion CV Team Dispatch

February 2022 News Roundup

February 01, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

May 2021 News Roundup

News Opinion CV Team Dispatch

May 2021 News Roundup

May 01, 2021

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

March 17, 2021

TCTMD’s Top 10 Most Popular Stories for September 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

October 01, 2020

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.